Big Market, Broad Plan: Bristol Shares Vision For Opdivo In Lung Cancer
Executive Summary
Releasing positive results for Opdivo in the Phase II CheckMate-063 study in highly refractory squamous-type NSCLC, Bristol explains its big tent development program, which tests the PD-1 inhibitor with immunotherapies as well as targeted drugs.
You may also be interested in...
Lung-MAP Patient Screening Should Translate To Cost-Savings
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.